Growth Metrics

Gilead Sciences (GILD) Free Cash Flow (QoQ) (2009 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn
10 Gsk 88.34 Bn 83.66 Bn -

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -22.26%
Dec 31, 2025 -21.18%
Sep 30, 2025 450.14%
Jun 30, 2025 -56.44%
Mar 31, 2025 -41.55%
Dec 31, 2024 -32.15%
Sep 30, 2024 248.79%
Jun 30, 2024 -43.47%
Mar 31, 2024 8.19%
Dec 31, 2023 19.66%
Sep 30, 2023 -25.74%
Jun 30, 2023 34.50%
Mar 31, 2023 -31.48%
Dec 31, 2022 -11.83%
Sep 30, 2022 63.11%
Jun 30, 2022 4.14%
Mar 31, 2022 -47.75%
Dec 31, 2021 -2.09%
Sep 30, 2021 41.74%
Jun 30, 2021 -10.14%
Mar 31, 2021 40.92%
Dec 31, 2020 -17.18%
Sep 30, 2020 -13.54%
Jun 30, 2020 91.54%
Mar 31, 2020 -46.78%
Dec 31, 2019 -2.78%
Sep 30, 2019 13.35%
Jun 30, 2019 60.97%
Mar 31, 2019 -36.10%
Dec 31, 2018 2.54%
Sep 30, 2018 60.27%
Jun 30, 2018 -38.00%
Mar 31, 2018 -18.75%
Dec 31, 2017 -1.25%
Sep 30, 2017 -24.63%
Jun 30, 2017 21.23%
Mar 31, 2017 -16.71%
Dec 31, 2016 -19.67%
Sep 30, 2016 -12.26%
Jun 30, 2016 20.95%
Mar 31, 2016 -29.77%
Dec 31, 2015 47.74%
Sep 30, 2015 -30.56%
Jun 30, 2015 -1.61%
Mar 31, 2015 95.41%
Dec 31, 2014 -26.99%
Sep 30, 2014 -4.52%
Jun 30, 2014 191.60%
Mar 31, 2014 113.34%
Dec 31, 2013 -8.07%
Sep 30, 2013 -21.13%
Jun 30, 2013 43.35%
Mar 31, 2013 45.18%
Dec 31, 2012 -35.74%
Sep 30, 2012 -45.84%
Jun 30, 2012 191.61%
Mar 31, 2012 -54.86%
Dec 31, 2011 14.31%
Sep 30, 2011 -9.14%
Jun 30, 2011 13.77%
Mar 31, 2011 14.85%
Dec 31, 2010 -3.72%
Sep 30, 2010 6.67%
Jun 30, 2010 3.66%
Mar 31, 2010 -29.02%
Dec 31, 2009 10.19%
Sep 30, 2009 39.92%
Jun 30, 2009 26.15%